A new aspect of tri-modal therapy with superselective intra-arterial chemotherapy in maxillary sinus carcinoma.
CONCLUSIONS
This superselective intra-arterial intervention technique enabled us to administer a higher dose of cisplatinum to the local lesion with a lower incidence of adverse issues by use of neutralizer, compared with the conventional methods.


OBJECTIVE
A wide variety of modalities, including surgery, radiotherapy, and chemotherapy, alone or in combination, have been reported for the treatment of maxillary sinus cancer. However, there is still much controversy with regard to the optimum treatment to obtain better local control and acceptable preservation of shape and function. Since 2001, we have performed superselective intra-arterial infusion chemotherapy in combination with radiotherapy and surgery aiming at a higher local control rate.


METHODS
This was a review of prospective collected data. The therapeutic design consisted of weekly intra-arterial infusion of high dose CDDP with concomitant radiotherapy and planned surgery performed during chemo-radiation therapy. From June 2001 to January 2004, 14 patients with squamous cell carcinoma of maxillary sinus underwent this treatment procedure at the University of Tokyo Hospital.


RESULTS
The local response rate with this combined therapy was 85.7%. Overall survival rates at 1 and 2 years were 78.6% and 56.2%, respectively, with median follow-up of 25.5 months.
Fujishiro
Yoshinori
Y
Department of Otolaryngology, Head and Neck Surgery, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Nakao
Kazunari
K
Watanabe
Kenta
K
Ebihara
Yasuhiro
Y
Nakamura
Naoki
N
Mori
Harushi
H
Hayashi
Naoto
N
Asakage
Takahiro
T
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology* / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008279:Magnetic Resonance Imaging; D008297:Male; D008443:Maxillary Sinus / Q000473:pathology*; D008875:Middle Aged; D009367:Neoplasm Staging; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000532:radiotherapy; D011879:Radiotherapy Dosage
D000970:Antineoplastic Agents; D002945:Cisplatin